Washington, October 14th / PRNewswire / -- Danaher Corporation ( NYSE : DHR ) announced on Tuesday a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader efforts to empower science through AI, the two companies are working together to combine Danaher's scientific instruments, automation technologies, laboratory workflow software, and domain expertise with NVIDIA's accelerated computing and AI technologies.
The goal of both parties is to help researchers move more quickly from prediction to experimental validation, forming a continuous learning cycle: experiments provide information for the models, and in turn, the models help design better experiments.
DanaH's President and CEO, Julie Sawyer Montgomery, stated: "DanaH is at the forefront of this transformation, which is reshaping the way science is conducted. We are working together around a common vision to drive more interconnected, adaptable, and accessible innovation, helping researchers overcome major challenges, and transforming discoveries into tangible benefits for humanity."
NVIDIA's Vice President of Medical Business, Kimberly Powell, stated: "The next era of scientific discovery will be driven by a continuous cycle between AI and experimentation. Together with Danaher, we will bring accelerated computing and physical AI into the laboratory – connecting models with instruments and real experimental data, allowing experiments to improve models, and models to design better experiments, helping researchers to compress what would otherwise take years of discovery into just a few months."
Danaher and NVIDIA are working to integrate AI into scientific instruments, including through edge computing with NVIDIA DGX Spark, leveraging RAPIDS for accelerated analysis and data processing, real-time inference, scientific reasoning, as well as basic model technologies, which include BioNeMo Open Models. The initial efforts will focus on a small selection of key instruments, with the potential to expand to a wider range of product portfolios in the future.
Both parties are also exploring how science AI and physics AI can support smarter instrument and laboratory workflows, such as the NVIDIA Cosmos world model and Omniverse digital twins, while ensuring that experimental evidence remains at the core of scientific decision-making.
This collaboration aims to advance Danaher's commitment to "connecting science" by integrating AI, accelerated computing, instruments, work processes, and experimental data, thereby generating experimental evidence. Danaher hopes to help researchers reduce the time and complexity between generating predictions from AI and taking action, while maintaining customers' choices regarding models, standards, and technology providers.
Forward-looking Statements and Other Information
The statements in this press release that are not strictly historical facts include information regarding Danaher's collaboration with NVIDIA, the expected scope, timing, expansion, capabilities, and benefits of the collaboration; the integration of AI technology into scientific instruments and laboratory workflows; the anticipated development and deployment of AI solutions to empower science; and the expected impact of these technologies on scientific research and discoveries. Such statements are considered “forward-looking” as defined by U.S. federal securities laws. There are numerous factors that could lead to significant differences between actual results, progress, and business decisions and those implied or described in these forward-looking statements, and therefore, reliance on such statements should not be excessive.
These factors include, but are not limited to: the impact of tariffs and related measures implemented by the United States and other countries; the impact related to debt obligations (including debts incurred for the acquisition of Masimo Corporation) on the company's operations and liquidity; the deterioration or instability of the global economy, the markets served by the company, and financial markets; uncertainties related to the development, deployment, and use of artificial intelligence in the company's business and products; the impact of global public health crises; uncertainties related to national laws or policies, including those aimed at protecting or promoting domestic interests and/or addressing foreign competition; the company's ability to successfully identify and complete appropriate acquisitions and strategic investments; the company's ability to integrate acquired businesses and achieve expected growth, synergies, and other benefits; contingent liabilities and other risks related to acquisitions, investments, strategic relationships, and divestitures (including risks associated with the acquisition of Masimo), as well as tax and other contingent liabilities related to past and future IPO, mergers, or spin-offs; the contraction or growth rate and cyclical nature of the markets served by the company; competition; the company's ability to develop and successfully market new products and technologies and expand into new markets; potential risks of improper behavior by employees, agents, or business partners; the company's compliance with applicable laws and regulations (including those related to off-label marketing and other regulations in the medical devices and healthcare industry); the results of clinical trials and market perception; the company's ability to effectively respond to cost cuts and other changes in the healthcare industry; the risk of information technology systems suffering from security vulnerabilities or other interruptions, or violations of data privacy laws; the risk of impairment of goodwill and other intangible assets; changes in exchange rates, tax audits, and tax rates and income tax liabilities; changes in tax laws applicable to multinational corporations; litigation, regulatory proceedings, and other contingent liabilities, including those related to intellectual property and environmental, health, and safety matters; and the U.S. government's rights over the company's capacity during national emergencies.Or the rights to intellectual property/production capacity developed using government funds; risks related to product, service, or software defects, product liability, and recalls; risks associated with manufacturing and operations; the impact of climate change, legal or regulatory measures to address climate change, and other sustainability issues, as well as the company's ability to meet regulatory requirements related to climate change and other sustainability issues or expectations of stakeholders; risks related to fluctuations in the cost and availability of supplies (including commodities) used by the company and the labor force required for operations; the relationship and performance of the company with channel partners; uncertainties related to third-party cooperation arrangements; the impact of reduced regulation on demand for the company's products and services; labor issues and the company's ability to attract, retain, and motivate outstanding employees; economic, political, geopolitical, legal, compliance, social, and business factors in the United States and outside of the United States (including elections, regulatory and policy changes or uncertainties, government shutdowns, and the impact of military conflicts such as those in the Middle East); disruptions and other effects caused by human and natural disasters; inflation; and the impact of the exclusive court clauses in the company's articles of association. For additional factors that may lead to significant differences between actual results and these forward-looking statements, please refer to the documents submitted by the company to the U.S. Securities and Exchange Commission, including the 2025 annual 10-K report and the 2026 second-quarter 10-Q quarterly report. The above forward-looking statements are as of the date of this press release, and except as required by applicable law, the company assumes no obligation to update or revise any forward-looking statements due to new information, future events, developments, or other reasons.
About Danaher
Danaher is a global leader in life sciences and diagnostic innovation, committed to harnessing the power of science and technology to improve human health. Lending on an interconnected ecosystem composed of industry-leading businesses, the company collaborates with its customers to address some of the most complex scientific and clinical challenges – accelerating the transformation of scientific discoveries into tangible benefits for humanity. With Danaher Business System, advanced science and technology, and proven innovation capabilities, the company helps to achieve faster and more accurate diagnoses, while reducing the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and best-in-class operations, Danaher’s approximately 60,000 employees worldwide are focused on creating lasting impacts, enhancing the quality of life globally, and building a healthier and more sustainable future. Innovation at the speed of life. For more information, please visit www.danaher.com.
